Replies to post #137404 on Biotech Values

[mcbio]

They have dozens of drugs in the pipeline, of course there will be failures. Not sure why they insist on acting like everything is always advancing perfectly. They also rarely meet their own projected development timelines, even for entering/completing phase 1 healthy volunteer studies. They need to prove they can do this before I get excited about the broadening pipeline.

What are your thoughts on chances of approval for mipomersen and potential revenues for ISIS? I listened to the Forbes interview linked to in #msg-72310849 and Crooke thinks the drug is, at a minimum, a several hundred million dollar to a billion dollar drug for just the initial indication. Even just a several hundred million dollar drug would presumably be transformative for ISIS.

[iwfal]

ISIS

I guess my standards are different. ISIS had been promising the SGLT2 phase 1 data for ages. They never presented it or issued a press release describing it. Instead, they bury it (and the program cancellation) at the end of a multi-hour R&D day and slide deck.

Thanks for the historical perspective that they don't provide detailed clinical results from the human trials. At least they didn't for SGLT2. Was that also true for all of their other products like Mipomersen or PTP1b and the other drugs they recently replaced with better technology?


As for them 'burying' it at the end of the presentation that doesn't bother me at all. I've seen much worse (e.g. either an 8K with no associated PR or year after year of nothing). That said, I didn't realize they didn't issue a PR to go along with the R&D Day presentation and do agree that this a significant knock against them.